Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients ≥ 18 years of age.~* Rheumatoid arthritis of ≤ 2 years duration.~* Disease Activity Score 28 (DAS28) \> 3.2.~* Swollen joint count (SJC) ≥ 4 of 66 joints, tender joint count (TJC) ≥ 6 of 68 joints.~* Rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) positive (if RF and anti-CCP negative \> 1 erosion required at screening).~* Erythrocyte sedimentation rate (ESR) ≥ 28 mm/h or C-reactive protein (CRP) ≥ 10 mg/L at screening.~Exclusion Criteria:~* Previous treatment with tocilizumab.~* Previous treatment with methotrexate or biologic agent.~* Rheumatic autoimmune disease other than rheumatoid arthritis (RA).~* History of or current inflammatory joint disease other than RA.~* Functional class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in RA.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- (A) Tocilizumab 8 mg/kg + placebo to methotrexate (Type: EXPERIMENTAL): Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.
- (B) Tocilizumab 8 mg/kg + methotrexate (Type: EXPERIMENTAL): Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.
- (C) Tocilizumab 4 mg/kg + methotrexate (Type: EXPERIMENTAL): Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.
- (D) Placebo to tocilizumab + methotrexate (Type: ACTIVE_COMPARATOR): Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).